In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 1317-39-1, name is Copper(I) oxide, introducing its new discovery. Quality Control of Copper(I) oxide
Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
Compounds of formula (I): STR1 wherein: R is an alkyl group; X is oxygen or sulfur; Y is hydrogen atom or –A–COOH, in which A is an alkylene group; Ar is aryl or substituted aryl group; and pharmaceutically acceptable salts and esters thereof, have use in the treatment or prophylaxis of diabetes, obesity, hyperlipemia, hyperglycemia, complications of diabetes, obesity-related hypertension and osteoporosis.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 1317-39-1, and how the biochemistry of the body works.Quality Control of Copper(I) oxide
Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”